Decreased plasma conc w/ antacid susp containing Al & Mg hydroxide. Increased rosuvastatin exposure w/ SLCO1B1 (OATP1B1) c.521CC & ABCG2 (BCRP) c.421AA. 10 mg: Vit K antagonists, gemfibrozil (need dose adjustment) & other lipid-lowering agents, cyclosporine, erythromycin, OC/hormone replacement therapy. Increased rosuvastatin exposure w/ protease inhibitors. Increased risk of myopathy w/ transporter protein inhibitors eg, ritonavir, atazanavir, lopinavir, darunavir, tipranavir, fosamprenavir. Ezetimibe. Eltrombopag. Dronedarone. Itraconazole. Aleglitazar. Silyramin. Fenofibrate. Rifampin. Ketoconazole. Fluconazole. 20 mg: Increased plasma conc & increased risk of myopathy w/ inhibitors of OATP1B1 & BCRP transporters. Increased AUC w/ PIs (eg, atazanavir, ritonavir). Increased Cmax
& AUC w/ gemfibrozil. Increased risk of myopathy w/ gemfibrozil, fenofibrate, other fibrates & niacin. Increased AUC w/ ezetimibe in hypercholesterolaemic subjects. Decreased Cmax
& AUC w/ erythromycin. Increased AUC w/ simeprevir, clopidogrel, lopinavir, eltrombopag, darunavir, tipranavir, dronedarone, itraconazole. Decreased AUC w/ baicalin. May either increase or decrease INR in patients taking vit K antagonists (eg, warfarin). Increased AUC of ethinyl estradiol & norgestrel.